News

TEDCO Announces Investment into Astek Diagnostics

TEDCO, Maryland’s economic engine for technology companies, announced a Seed Funds investment of $250,000 into Astek Diagnostics, a life sciences company fighting antibiotic resistance through innovative technology. In addition to this investment through the Life Sciences Investment Fund – a funding opportunity under the umbrella of TEDCO’s Seed Funds – Astek Diagnostics has received an additional $325,000 from the State Small Business Credit Initiative (SSBCI) funding.

Mustafa Al-Adhami“Without the proper diagnostic procedures, patients and physicians risk advancing the vicious cycle of antibiotic resistance,” explained Mustafa Al-Adhami, PhD, CEO of Astek Diagnostics. “This cycle leads to the creation of more resilient bacteria that require more complicated treatments. But with the help of our device, the Jiddu, we can put an end to this disastrous cycle. The Jiddu provides physicians with more diagnostic material, allowing them to make informed decisions about the best prescribing methods to use.”

Astek Diagnostics, based in Baltimore, Md., is a business that is focused on creating a platform to determine antibiotic sensitivity. Through this venture, the company developed the Jiddu. This device is a cost-effective and efficient diagnostic platform that provides physicians with adequate accurate information to diagnose and treat urinary tract infections, finding any antibiotic susceptibility and preventing the use of ineffective or excessive antibiotics—a practice that can cause the creation of antibiotic resistant bacteria.

Astek Diagnostics“The issue of bacteria resiliency affects us all,” said Teddy Gresser, director of Seed Funds at TEDCO. “Astek’s determination to fight against antibiotic resistance has potential to not only be a successful business venture, but also to change the way physicians operate, allowing for more accuracy and less complications. TEDCO is eager to witness Astek Diagnostics’ journey, what innovations they can create, and how their business will impact Maryland.”

Astek is a long-standing TEDCO portfolio company, having received funding from TEDCO’s Pre-Seed Builder Fund, Maryland Innovation Initiative (MII), and successfully participated in TEDCO’s SBIR/STTR Proposal Lab.

The Seed Fund is one of the many funding opportunities available through TEDCO; for information on other opportunities, or information on how to apply, entrepreneurs should visit https://www.tedcomd.com/funding.

Recent News

03/25/2026

Grenova Appoints New Chief Executive Officer to Lead Next Phase of Growth Across Global Automation Platform

Grenova today announced the appointment of Ted Hull as Chief Executive Officer. Hull will lead Grenova and its automation divisions, Peak Robotics and Peak Analysis & Automation (PAA), guiding the organization through its next phase of growth as a global platform delivering automation-ready solutions to laboratories world-wide. Grenova and its division partners are backed by

03/25/2026

Virginia Startups Raise Record $2.9 Billion in Venture Capital Investment in 2025 – Highest in Commonwealth History

Virginia Innovation Partnership Corp. (VIPC) today announced that the National Venture Capital Association (NVCA) reported Virginia attracted $2.9 billion in venture capital investment in 2025, marking an all-time high for the Commonwealth according to the 2025 Q4 Pitchbook-NVCA Venture Monitor Report.1 This record level of investment reflects the continued growth and momentum of Virginia’s startup

03/24/2026

Prolight reports positive Traumatic Brain Injury (TBI) biomarker results with BRAINBox Solutions, confirming broad assay potential of the Psyros™ POC platform

Prolight Diagnostics, a leader in point-of-care (POC) technology, today announces positive results from a collaboration with BRAINBox Solutions, a leader in multi-modality diagnostic and prognostic tests for traumatic brain injury (TBI). The analytic evaluation shows strong performance across a unique combination of three traumatic brain injury biomarkers, demonstrating the ease with which multiple novel markers can be transferred onto the Psyros uniquesingle-molecule-counting platform and reinforcing its potential to improve